September 2024 FDA Recall Ryaltris by Glenmark Pharmaceuticals Inc., Usa
D-0006-2025 - Defective Delivery System

This Class II drug recall was voluntarily initiated by Glenmark Pharmaceuticals Inc., Usa on September 24, 2024 for the product Ryaltris. The FDA reported the reason for recall as defective delivery system. The product was distributed Nationwide and the recall is currently ongoing.

Recall Number: D-0006-2025

Reason for Recall
Defective Delivery System: The dip tube is clogged causing the spray not to work.
Initiated
09-24-2024
Reported
10-09-2024
Quantity
45,504 bottles

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Glenmark Pharmaceuticals Inc., USA
Nationwide in the USA
Ryaltris (olopatadine hydrochloride and mometasone fluorate) Nasal Spray, 665 mcg/25 mcg per spray, 240 Metered Sprays/bottle, 29 g net fill weight, Distr. by Hikma Specialty USA Inc., Columbus, OH 43328, hikma, Glenmark Specialty SA. NDC 59467-700-27.

Batch or Lot Expiration Information

Lot# Lots 14230425, Exp Date, Nov-25; 14240024, Exp Date Dec-25; 14240029, Exp Date Dec-25; 14240076, Exp Date Jan-26; 14240082 Exp Date, Jan-26, 14240090, Exp Date Jan-26; and 14240100, Exp Date Jan-26

Affected Packages Involved in this Recall